Some Peculiarities of Registration of Pharmaceutical Trademarks
Аннотация
The number of cases where pharmaceutical trademarks are the subject of proceedings has skyrocketed in recent years. It evidences the relevance of an analysis of the peculiarities of trademark protection in relation to pharmaceutical trademarks, which is presented in the article. Close attention is paid to an analysis of registration of designations identical to INN or derivatives from INN in the Russian Federation. Relying on analysis of the practice of the Chamber for Patent and Trademark Disputes and courts, the authors conclude that designations identical to INN are unable to benefit from trademark protection as non-distinctive and contradictory to public interests. As to designations comprising or resembling INN to some extent, such designations have chances to be registered as trademarks if they are not considered as INN derivatives. A trademark is recognized as an INN derivative if it is similar to INN to the degree of confusion. Ultimately, the authors reach the conclusion that current Russian legislation does not require any amendments to enhance practice on consideration of cases where designations identical or confusingly similar to INN are involved, since such cases can be successfully inserted into general provisions governing trademarks. Another issue which is also examined in the article is the current approach of the Chamber for Patent and Trademark Disputes and courts to the assessment of similarity in relation to pharmaceutical trademarks, especially the practice of applying the so-called «Three Letter Rule». The authors hold the view that prioritization of the «Three Letter Rule» is a negative trend, since following the «Three Letter Rule» blindly cannot replace due assessment of the designation. The authors attempt to prove this by providing examples of flaws inherent in situations including the «Three Letter Rule.”
Литература
Brennan H. (2015) Cost of Confusion: The Paradox of Trademarked Pharmaceuticals, 22 Mich. Telecomm. & Tech. L. Rev. 1. Available at: http://repository.law.umich.edu/mttlr/vol22/iss1/1
Ferrand L., New B. (2003) Syllabic length effects in visual word recognition and naming. Acta Psychol, vol. 113, p. 167-183
Herberholz D. (2007) Curing Confusion: An Overview of the Regulatory Complexities of Obtaining Pharmaceutical Trademarks and a Prescription for Reform, 8 Minn. J.L. Sci. & Tech. 97. Available at: http://scholarship.law.umn.edu/mjlst/vol8/iss1/4 (accessed: 10.04.2016)
Jagla F., Umansky B. (2009) Naming the Product: The Intersection of FDA and Trademark Law, IP Litigator, vol. 15, no 1, pp. 13-19.
Kuzcow M. (1979) The FTC and the Generic Doctrine: A New Rx for Pharmaceutical Trademarks, 15 Tulsa L. J. 327, p. 327-347. Available at: http://digitalcommons.law.utulsa.edu/cgi/viewcontent.cgi?article=1515&context=tlr (accessed: 10.04.2016)
Mosback H. (2013) Protection of pharmaceutical trade marks in Europe: an overview, Journal of Intellectual Property Law & Practice 8 (1), p. 69-77.
Pharmaceutical Trademarks 2013/2014: A Global Guide. Available at: http://www.worldtrademarkre-view.com/Intelligence/Pharmaceutical-Trademarks/2013 (accessed: 10.04.2016)
Razumova G.V. (2012) Protivorechie obshchestvennym interesam kak osnovanie dlya otkaza v registratsii tovarnogo znaka [Contradicting Public Interests as a Reason to deny the Registration of a Trademark]. Imushchestvennye otnosheniya v Rossiyskoy Federatsii, no 10. SPS Konsul'tantPlyus Robinov A.A. (2013) Novoe v praktike Vysshego Arbitrazhnogo Suda Rossiyskoy Federatsii [New in the Practice of the RF Higher Arbitration Court]. Imushchestvennye otnosheniya v Rossiyskoy Federatsii, no 8. SPS Konsul'tantPlyus
Sadovskiy P., Demina M. (2015) Spory ob intellektual'noy sobstvennosti v sfere farmatsevtiki: poslednie tendentsii [Intellectual Property Disputes: Trends in Pharmaceutics]. Arbitrazhnye spory, no 1. SPS Konsul'tantPlyus
Schwartz V. E., Goldberg Ph., Silverman C. (2013) Warning: shifting liability to manufacturers of brandname medicines when the harm was allegedly caused by generic drugs has severe side effects, Fordham Law ReviewVol. 81, p. 1835-1879. Available at: http://fordhamlawreview.org/wp-content/uploads/assets/pdfs/Vol_81/Schwartz_March.pdf (accessed: 10.04.2016)
Sim K. R., Robertson H. E. (2008) The Canadian Regime for Protecting Against Pharmaceutical Trademark Confusion and Mistakes, Trademark Reporter, The Law Journal of the International Trademark Association. Vol. 98 No. 5, p. 1253-1277. Available at: http://www.smart-biggar.ca/assets/tm_reporter_vol98_no5.pdf (accessed: 10.04.2016)
Smith G. V. (1997) Trademark Valuation. N.Y.: John Wiley & Sons, 293 p.
Williamson C. M. (2013) A Morphological Study of Drug Brand Names Honors Theses. Paper 104. Zahl A. (2015) International Pharmaceutical Law and Practice, LexisNexis, 1280 p.
Copyright (c) 2016 Право. Журнал Высшей школы экономики

Это произведение доступно по лицензии Creative Commons «Attribution-ShareAlike» («Атрибуция — На тех же условиях») 4.0 Всемирная.












